Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

By Barzilai Nir   Guo Hua   Mahoney Erin M.   Caporossi Suzanne   Golm Gregory T.   Langdon Ronald B.   Williams-Herman Debora   Kaufman Keith D.   Amatruda John M.   Goldstein Barry J.   Steinberg Helmut  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 1049-1058

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 309-312

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 936-948

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 453-457

John Wiley & Sons Inc

Access to resources Recommend Favorite